Ep. 119: Phase 2 HOPE clinical trial results

Moderator: Theodoros M. Mavridis (Dublin, Ireland)

Guest: Messoud Ashina (Glostrup, Denmark)

In this episode Theodoros M. Mavridis and Messoud Ashina delve into the findings of the Phase 2 HOPE clinical trial, which assesses the efficacy and safety of Lu AG09222, a monoclonal antibody that targets the PACAP pathway. They explore the potential of this innovative treatment for migraine prevention while highlighting the critical role of the PACAP pathway in migraine pathophysiology.